CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months. The eligible patients must have intermediate or high risk of recurrence, as defined by specified clinical and biologic criteria. Prior use of CDK4/6 inhibitors is permitted. The primary endpoint of the study is Invasive breast cancer-free survival (IBCFS) and main secondary endpoints include Invasive disease-free survival (IDFS), Distant relapse-free survival (DRFS), Overall survival (OS), Safety and Clinical Outcome Assessments (COAs).
Patients will be followed for 10 years from randomization of the last patient.
Inclusion Criteria:
Exclusion criteria:
information.center@astrazeneca.com1-877-240-9479
az-bcsl@careboxhealth.com1-877-400-4655
CABA, C1119ACN, Argentina
Capital Federal, C1417DTB, Argentina
Ciudad Autónoma Buenos Aires, 1125, Argentina
Ciudad de Buenos Aires, 1280, Argentina
Ciudad de Buenos Aires, C1118AAT, Argentina
Ciudad de Buenos Aires, C1426ANZ, Argentina
Wein, 1130, Austria
Huangpu District, 200025, China
Pragues, 18081, Czechia
Epagny Metz-Tessy, 74370, France
Plerin SUR MER, 22190, France
West Bengal, 700 156, India
Hidaka-shi, 350-1298, Japan
Hirakata-shi, 573-1191, Japan
Isehara-shi, 259-1193, Japan
Kitaadachi-gun, 362-0806, Japan
Kurume-shi, 830-0013, Japan
Ota-shi, 373-8550, Japan
Sagamihara-shi, 252-0375, Japan
Shinagawa-ku, 142-8666, Japan
Suita-shi, 565-0871, Japan
Sunto-gun, 411-8777, Japan
Takasaki-shi, 370-0829, Japan
Alc. Cuauhtémoc, 06100, Mexico
Jeonnam, 58128, South Korea
Seongbuk-Gu, 2841, South Korea
Phisanulok, 65000, Thailand
Rachathewi, 10400, Thailand